|1.||Pomel, Sébastien: 1 article (12/2015)|
|2.||Vacus, Joël: 1 article (12/2015)|
|3.||Bories, Christian: 1 article (12/2015)|
|4.||Kesavan, Ventikasamy: 1 article (12/2015)|
|5.||Cojean, Sandrine: 1 article (12/2015)|
|6.||Vieira, Nashira Campos: 1 article (12/2015)|
|7.||Loiseau, Philippe M: 1 article (12/2015)|
|8.||Figadère, Bruno: 1 article (12/2015)|
|9.||Balaraman, Kaluvu: 1 article (12/2015)|
|10.||Moussa, Fathi: 1 article (12/2015)|
12/01/2015 - "2-n-propylquinoline (2-n-PQ) had shown interesting in vivo antileishmanial activities after administration by oral route on leishmaniasis animal models. "
09/04/1998 - "A high-performance liquid chromatographic method was developed for the specific determination of 2-n-propylquinoline, a new anti-leishmaniasis drug, in plasma and liver homogenates of mice. "
|2.||Chagas Disease (American Trypanosomiasis)
|3.||Visceral Leishmaniasis (Kala Azar)
03/01/1994 - "We now report the antileishmanial activity of four 2-substituted quinoline alkaloids, namely chimanine D or 2-(1',2'-trans-epoxypropyl) quinoline (I), 2-n-propylquinoline (II), 2-styrylquinoline (III) and 2-(2'-hydroxypropyl) quinoline (IV), for experimental treatment of visceral leishmaniasis in infected BALB/c mice. "
11/01/2001 - "Experimental treatment of chronic Trypanosoma cruzi infection in mice with 2-n-propylquinoline."
11/01/2001 - "The reference drug and 2-n-propylquinoline were administered 60 days post-infection for 30 days at 25 mg/mL. At 35 days post-treatment, the serological tests (ELISA) of the 2-n- propylquinoline-treated mice were significantly different from the controls (p = 0.01) and the benznidazole-treated mice (p = 0.03), while this was not the case at 85 days post-treatment. "